These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37105074)

  • 21. Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
    Chatterjee S; Dhal AK; Paul S; Sinha S; Das B; Dash SR; Kundu CN
    J Cancer Res Clin Oncol; 2022 Dec; 148(12):3521-3535. PubMed ID: 35962813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance.
    Lovsund T; Mashayekhi F; Fitieh A; Stafford J; Ismail IH
    Cells; 2023 Jul; 12(14):. PubMed ID: 37508568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multi-therapies Based on PARP Inhibition: Potential Therapeutic Approaches for Cancer Treatment.
    Zhang J; Gao Y; Zhang Z; Zhao J; Jia W; Xia C; Wang F; Liu T
    J Med Chem; 2022 Dec; 65(24):16099-16127. PubMed ID: 36512711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
    Lau CH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer.
    Wang T; Liu W; Shen Q; Tao R; Li C; Shen Q; Lin Y; Huang Y; Yang L; Xie G; Bai J; Li R; Wang L; Tao K; Yin Y
    Cancer Sci; 2023 Nov; 114(11):4184-4201. PubMed ID: 37702298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
    Dulaney C; Marcrom S; Stanley J; Yang ES
    Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Studying the Immunomodulatory Functions of PARP1 and PARP2 in Mouse Models of Cancer.
    Lutfi N; Martínez C; Yélamos J
    Methods Mol Biol; 2023; 2609():195-212. PubMed ID: 36515837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
    Vormoor B; Curtin NJ
    Curr Opin Oncol; 2014 Jul; 26(4):428-33. PubMed ID: 24840521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
    Duma N; Gast KC; Choong GM; Leon-Ferre RA; O'Sullivan CC
    Curr Oncol Rep; 2018 Jun; 20(8):63. PubMed ID: 29884921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks.
    Blessing C; Mandemaker IK; Gonzalez-Leal C; Preisser J; Schomburg A; Ladurner AG
    Mol Cell; 2020 Dec; 80(5):862-875.e6. PubMed ID: 33275888
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
    Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
    J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment.
    Catalano M; Francesco Iannone L; Cosso F; Generali D; Mini E; Roviello G
    Expert Opin Ther Targets; 2022 Nov; 26(11):923-936. PubMed ID: 36519314
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair.
    Altwerger G; Ghazarian M; Glazer PM
    Semin Cancer Biol; 2024 Jan; 98():11-18. PubMed ID: 38029867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
    Kim DS; Camacho CV; Kraus WL
    Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
    Zheng F; Zhang Y; Chen S; Weng X; Rao Y; Fang H
    Biomed Pharmacother; 2020 Mar; 123():109661. PubMed ID: 31931287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
    Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
    Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Moutafi M; Economopoulou P; Rimm D; Psyrri A
    Oral Oncol; 2021 Jun; 117():105292. PubMed ID: 33862558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.